The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

Background Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. Objective The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. Methods We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. Results In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. Conclusions The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.

[1]  Dyfrig A Hughes,et al.  Taxonomy for methods of resource use measurement. , 2015, Health economics.

[2]  W. Greiner,et al.  Die deutsche Version des EuroQol-Fragebogens , 1998, Zeitschrift für Gesundheitswissenschaften = Journal of public health.

[3]  W. Zeller.  Immuntherapeutika und Zytostatika , 2001 .

[4]  Floyd J. Fowler,et al.  Improving Survey Questions: Design and Evaluation , 1995 .

[5]  Terry K Koo,et al.  A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. , 2016, Journal Chiropractic Medicine.

[6]  M. Atkinson,et al.  Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  B. Jönsson,et al.  Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis , 2006, The European Journal of Health Economics.

[8]  R. Holle,et al.  [Calculation of standardised unit costs from a societal perspective for health economic evaluation]. , 2015, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[9]  A. Wundes,et al.  Contribution of intangible costs to the economic burden of multiple sclerosis , 2010, Journal of medical economics.

[10]  G. Kobelt,et al.  Burden and cost of multiple sclerosis in Brazil , 2019, PloS one.

[11]  B. Sharrack,et al.  The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis , 1999, Multiple sclerosis.

[12]  John Piepenbrink.  DRESDEN , 2006, Camden Fifth Series.

[13]  E. Havrdová,et al.  Real-Life Outcome in Multiple Sclerosis in the Czech Republic , 2019, Multiple Sclerosis International.

[14]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[15]  W. Greiner,et al.  Validating the EQ-5D with time trade off for the German population , 2005, The European Journal of Health Economics.

[16]  D. Stull,et al.  Optimal recall periods for patient-reported outcomes: challenges and potential solutions , 2009, Current medical research and opinion.

[17]  R. Dodel,et al.  Economic Burden in a German Cohort of Patients with Multiple Sclerosis , 2011, European Neurology.

[18]  J Raftery,et al.  Costing in economic evaluation , 2000, BMJ : British Medical Journal.

[19]  W. B. van den Hout.  The value of productivity: human-capital versus friction-cost method , 2009, Annals of the rheumatic diseases.

[20]  Jenny Berg,et al.  New insights into the burden and costs of multiple sclerosis in Europe , 2017, Multiple sclerosis.

[21]  P Lindgren,et al.  Costs and quality of life of patients with multiple sclerosis in Europe , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  G. Phillips,et al.  The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms , 2017, Multiple sclerosis.

[23]  A. Gustavsson,et al.  Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries , 2012, Multiple sclerosis.

[24]  T. Ziemssen,et al.  Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol , 2016, JMIR research protocols.

[25]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[26]  Dyfrig A Hughes,et al.  Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  L. Doward,et al.  The development of patient-reported outcome indices for multiple sclerosis (PRIMUS) , 2009, Multiple sclerosis.

[28]  Raimar Kern,et al.  The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice , 2015, BMC Neurology.

[29]  S. Noble,et al.  Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  K. Alexanderson,et al.  Cost of Illness of Multiple Sclerosis - A Systematic Review , 2015, PloS one.

[31]  Tjalf Ziemssen,et al.  Differentiating societal costs of disability worsening in multiple sclerosis , 2019, Journal of Neurology.

[32]  W. Greiner,et al.  Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation , 2014 .

[33]  W. B. van den Hout,et al.  The value of productivity: human-capital versus friction-cost method , 2009, Annals of the rheumatic diseases.